信息Denka Introduces New Production Facility for Thermally Conductive Sheet for 5G/xEV to Shibukawa Plant and Doubles Production Capacity

IR信息Denka Establishes the Denka Group ESG Basic Policies

IR信息FY2021 Second Quarter Financial Results Presentation Summary

IR信息FY2021 Second Quarter Financial Results Presentation Materials

IR信息FY2021 Second Quarter Summary of Consolidated Financial Statements

IR信息The Board of Directors of Denka Resolves on the Selection of the Prime Market as the New TSE Market Segment

信息Notice of Voluntary Recall of Certain Lots of the COVID-19 Rapid Antigen Test Kit

信息COVID-19 Rapid Antigen Test Kits Start of Sales in the U.S. Market from November ～Our Business Partner Xtrava Health has obtained an EUA from the U.S.FDA～

信息关于改组成立电化（上海）管理有限公司 ～作为地区总部，扩大在中国的业务，并加强企业管理～

信息Denka Concludes ESG/SDG-Linked Syndicated Loan with Sumitomo Mitsui Banking Corporation

IR信息FY2021 First Quarter Financial Results Presentation Summary

信息Denka Supplies COVID-19 Rapid Antigen Test Kits to Japanese Government (Updated)

IR信息FY2021 First Quarter Financial Results Presentation Materials

IR信息FY2021 First Quarter Summary of Consolidated Financial Statements

信息Denka Completes Construction of Production Facility to Boost Production of High Functional Transparent Polymers (MS Resin) at Base in Singapore ~Doubling Annual Production Capacity to Approx. 140,000 tons and Enhancing Specialty Business~

信息Denka Receives "Semiconductor of the Year 2021" Award for Development of Denka Spherical Magnesia

信息本日（6月16日）开始销售用于新型冠状病毒变异位点检测的研究试剂 ～可同时检测10种变异位点，为流行病学研究做出贡献～

信息Denka Receives Approval for Marketing of the DELYTACT (G47Δ) Oncolytic Virus in Japan ～Worlds' First Oncolytic Virus against Malignant Glioma～

信息Denka Supplies COVID-19 Rapid Antigen Test Kits to Japanese Government ～The kits will Contribute to Efforts for Preventing the Occurrence of Clusters and Stopping the Spread of Infections.～

IR信息FY2020 Financial Results Presentation Materials

信息经营计划"Denka Value-Up" 中间评审

IR信息FY2020 Summary of Consolidated Financial Results

IR信息FY2020 Summary of Consolidated Financial Statements

IR信息Denka Value-Up 中间评审与2022财年数值目标

IR信息Denka Value-Up ～2022财年数值目标与今后2年的措施～

信息关于新型冠状病毒变异株检测系统的开发 ～使用一种试剂同时检测多种变异株，减少检测工作量和实现快速检测～

信息可同时检测新型冠状病毒和流感病毒的试剂盒提交日本药事审批

信息新年致辞